

# TBG deficiency and Central Congenital Hypothyroidism (CH-C): Our experience in neonatal screening with TSH and T4


Chueca M<sup>1</sup>, Grau G<sup>2</sup>, Bertholt L<sup>3</sup>, Artola E<sup>4</sup>, Fernández C<sup>5</sup>, Sarasua A<sup>6</sup>, Rodriguez A<sup>2</sup>, Vela A<sup>2</sup>, Belza A<sup>1</sup>, Berrade S<sup>1</sup>, Dura T<sup>1</sup>, Alonso P<sup>3</sup>, Puges L<sup>4</sup>, Diez I<sup>6</sup>, Espada M<sup>7</sup>, Ederra M<sup>8</sup>, Ascunce N<sup>8</sup>, Porrás B<sup>9</sup>, Rica I<sup>2</sup>.

<sup>1</sup>Complejo Hospitalario Navarra, Pamplona, Spain. <sup>2</sup>Cruces Hospital, Barakaldo, Spain. <sup>3</sup>Marques de Valdecilla Hospital, Santander, Spain. <sup>4</sup>Donostia Hospital, San Sebastian, Spain. <sup>5</sup>Basurto Hospital, Bilbao, Spain. <sup>6</sup>Araba Hospital, Vitoria, Spain. <sup>7</sup>Public Health, Basque Country, Zamudio, Spain. <sup>8</sup>Public Health, Navarre, Pamplona, Spain. <sup>9</sup>Public Health, Cantabria, Santander, Spain.

The new 2020 ESPE guidelines on congenital hypothyroidism (CH) include detection of CH-C in screening programs. CH-C must be distinguished from T4-binding globulin (TBG) deficiency. It is important to determine whether thyroid function tests reliably separate CH-C from TBG deficiency. TBG (*blood thyroxine transporter globulin*) deficiencies, which is common in the population and does not carry a risk of mental retardation.

## Objective

- Analyze CCH detection program results from 3 Autonomous Communities (AC) of Spain, at our Public Health Regulatory Laboratory (LNSP):
- TSH and total T4 (TT4) in dried blood spot (DBS) at initial screening (48 hours of life) and at retesting.
  - Describe the characteristics of neonates with screening compatible with CCH.
  - Consider whether TBG deficiency (TBGD) is an added difficulty in said study.




## Material and methods

Retrospective study (May 2016-May 2020) of all neonates  $\geq 33$  weeks and/or  $\geq 1500$  grams referred to the Child Endocrinology services of 3 AC from the LNSP due to low T4 ( $< 6 \mu\text{g/dL}$ ), out of a total of 105,858 CH screenings.

The positives for low T4 ( $< 6 \mu\text{g/dL}$ ) in the retesting compatible with CCH (low T4 and low/normal TSH) were analyzed. After determination in serum, the diagnoses were:

1. CCH: low free T4 (FT4) and low/normal TSH
2. TBG deficiency (TBGD): normal FT4 and TSH
3. Hyperthyrotropinemia: normal FT4 and elevated TSH
4. Euthyroid sick syndrome.




Clinical and laboratory variables were compared between CCH and TBGD. The evolution of the cases considered CCH was assessed.

## Results

Forty-four neonates were referred due to low TT4, 15 corresponding to primary CH and 29 cases were compatible with CCH.


SCREENING WITH LOW T4:



The final diagnosis of the positives with initial suspicion of CCH was: 15 TBGD, 8 CCH, 5 hyperthyrotropinemia and 1 euthyroid sick syndrome. CCH prevalence in this period was 1/13,333 screenings.

U Mann-Whitney	CCH (mean $\pm$ DE) n=8	TBGD (mean $\pm$ DE) n=15	
Gestational age (weeks)	38,7 $\pm$ 1,9	38,3 $\pm$ 2,0	ns
SDS-weight at birth	0,4 $\pm$ 0,9	-0,3 $\pm$ 1,0	ns
SDS-Lenght at birth	0,5 $\pm$ 0,4	-0,4 $\pm$ 1,1	ns
TSH screening (mIU/L)	1,8 $\pm$ 0,2	1,9 $\pm$ 0,9	ns
TT4 screening (mcg/dL)	2,2 $\pm$ 0,2	4,4 $\pm$ 0,9	0.000*
TSH retesting (mIU/L)	2,0 $\pm$ 0,0	1,9 $\pm$ 0,2	ns
TT4 retesting (mcg/dL)	2,3 $\pm$ 1,4	3,7 $\pm$ 1,3	0.034*
TSH serum (mIU/L)	2,8 $\pm$ 1,8	3,8 $\pm$ 0,9	ns
FT4 (ng/dL)	0,7 $\pm$ 0,1	1,5 $\pm$ 0,4	0.000*

Statistically significant differences were found in FT4 values when comparing CCH and TBGD.



### Genetic analysis of the patients with CCH

	MRI HPT-HPF	GENETICS
Patient 1	NORMAL	CCDC59 p.G26R 0.7-1.2%
Patient 2	pituitary hypoplasia	GATA2 p.P161A 0.3% / ZNHX3 p.N1025S n.d.
Patient 3	NORMAL	GATA2 P.p161a 0,3% / ZFH3 inframe deletion
Patient 4	NORMAL	in process
patient 5	pituitary hipoplasia	IGSF1 p.M1076I 0,49% / DROSHA p.P56S 0,68%
Patient 6	pituitary hypoplasia	in process
Patient 7	NORMAL	
Patient 8	NORMAL	Not done

All CCH started treatment with levothyroxine with a median age of 9.5 days (7-155). 1 patient with multiple hormonal deficiency and 7 patients with isolated CCHs have been diagnosed (according to evolution data and/or genetic results). 6 out of 8 patients with CCH also had TBGD.

## Conclusions

- The determination of TT4 in neonatal screening has diagnosed 8 patients with CCH.
- TBG defect is very common in the population; TBGD diagnosis does not exclude a CCH, since they can coexist.
- Genetic studies would help to confirm CCH diagnosis